MedTrace Logo

Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer

NCT02751827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 312

Last updated 2025-08-24

Study results available
· View outcomes & findings →

Summary

In order to assess the important issue of the safety of antiangiogenic TKI in geriatric population we set up this project which aims to identify, among clinical, biological, pharmacokinetic data, predictive factors for severe toxicity of antiangiogenic TKI (sunitinib, sorafenib, pazopanib, regorafenib, axitinib) in patients over 70 year-old.

Conditions

Interventions

OTHER

Blood sample

One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic

Sponsors & Collaborators

  • Agence Nationale de sécurité du Médicament

    collaborator OTHER

  • Institut Bergonié

    lead OTHER

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-02
Primary Completion
2019-11-19
Completion
2019-11-19

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751827 on ClinicalTrials.gov